Lung Cancer Clinical Trial
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while sparing normal cells) and to establish a safe multi-dose schedule of the virus for the treatment of solid tumors where enhanced expression of ICAM-1 and/ or DAF receptor occurs.
This trial consists of 2 sequential parts: VLA-009 (Part A) conducted only in the UK and employed CVA21 as a monotherapy in NSCLC, castrate-resistant prostate cancer, melanoma and bladder cancer. VLA-009 (Part B) conducted in the US, AUS and UK employs CVA21 with pembrolizumab in NSCLC and bladder cancer.
Both VLA-009A and VLA-009B are open-label, multi-center, ascending dose escalation (3+3 design) dose-finding and signal-seeking studies.
Part A of the study is now complete and closed to enrolment. Part B is currently enrolling.
Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma.
VLA009A: Locally advanced and/or metastatic disease for which curative surgery and/or radiation therapy is not possible and judged not to be a candidate for the current standard of care treatment. VLA009B: locally advanced and/or metastatic disease and judged to be a candidate for pembrolizumab to be used in combination with CVA21.
All subjects in Cohort 3 or Phase 2 dose (P2D) must have a lesion accessible for FNA or core or open biopsy on day 8 of the first treatment cycle.
No CVA21 neutralising antibody (≤ 1:16)
Measurable or evaluable disease
Second primary malignancy within the past 2 years (except non-melanoma skin cancer, in situ carcinoma of the cervix, breast cancer)
Concurrent immunosuppressive therapy and no known immunosuppressive disease other than primary tumour
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 18 Locations for this study
Santa Monica California, 90404, United States
Coral Gables Florida, 33146, United States
Niles Illinois, 60714, United States
Detroit Michigan, 48201, United States
New York New York, 10065, United States
Portland Oregon, 97213, United States
Philadelphia Pennsylvania, 19111, United States
Dallas Texas, 75390, United States
Salt Lake City Utah, 84112, United States
Southport Queensland, 4216, Australia
Clayton Victoria, 3168, Australia
Fitzroy Victoria, 3065, Australia
Geelong Victoria, 3220, Australia
Richmond Victoria, 3121, Australia
Subiaco Western Australia, 6008, Australia
Chelsea , SW3 6, United Kingdom
Guildford , GU2 7, United Kingdom
Leeds , LS9 7, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.